CI-1040
Information
- Drug Name
- CI-1040
- Description
- Entry(CIViC)
CIViC
[No Data.]
Annotation
Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
---|---|---|---|---|---|---|
CI-1040: MEK inhibitor. Lentiviral vectors were us... | BCL2 | BCL2 OVEREXPRESSION | Resitance or Non-Reponse | true | MMMP | detail |
CI-1040: MEK inhibitor. Lentiviral vectors were us... | MCL1 | MCL1 OVEREXPRESSION | Resitance or Non-Reponse | true | MMMP | detail |
CI-1040 is a MEK inhibitor | MAP2K1 | MAP2K1 P124L | Resitance or Non-Reponse | true | MMMP | detail |
CI-1040 is a MEK inhibitor | MAP2K1 | MAP2K1 I103N | Resitance or Non-Reponse | true | MMMP | detail |
CI-1040 is a MEK inhibitor | MAP2K1 | MAP2K1 L115P | Resitance or Non-Reponse | true | MMMP | detail |
CI-1040 is a MEK inhibitor | MAP2K1 | MAP2K1 F129L | Resitance or Non-Reponse | true | MMMP | detail |
CI-1040 is a MEK inhibitor | MAP2K1 | MAP2K1 UNKNOWN | Resitance or Non-Reponse | true | MMMP | detail |
CI-1040 is a MEK inhibitor | MAP2K1 | MAP2K1 Q56P | Resitance or Non-Reponse | true | MMMP | detail |
This mutation reduces BMF interaction with DLC2, w... | BMF | BMF A69P | Sensitivity | true | MMMP | detail |
CI-1040: MEK inhibitor. BMF expression is necessar... | BMF | BMF UNDEREXPRESSION | Resitance or Non-Reponse | true | MMMP | detail |
CI-1040 is a MEK inhibitor. Mutation of BRAF is as... | BRAF | BRAF V600E | Sensitivity | true | MMMP | detail |
NCT ID | Status | Phase | Summary | Start date | Completion date |
---|---|---|---|---|---|
NCT00033384 | Completed | Phase 2 | CI-1040 in Treating Patients With Advanced Breast, Colon, Pancreatic, or Non-Small Cell Lung Cancer | February 2002 | November 2003 |
NCT00034827 | Completed | Phase 2 | A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung, Breast, Colon and Pancreatic Cancer | January 2002 | May 2003 |
- Target (Drug list of Screening Committee of Anticancer Drugs)
- MAPK/ERK kinase (MEK)
- Synonym (Drug list of Screening Committee of Anticancer Drugs)
- PD184352